RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion

Class

Retinoid / RAR agonist (differentiation-inducing agent)

Pathway

Retinoic acid receptor signaling driving terminal myeloid differentiation of APL blasts

Notes

original target text: RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL

Retinoic acid receptor alpha (RARA) is a nuclear hormone receptor that normally pairs with a partner protein (RXR) and binds retinoic acid, a vitamin A derivative, to switch on genes needed for immature myeloid blood cells to mature into functional white blood cells. In acute promyelocytic leukemia (APL), a chromosomal rearrangement fuses RARA to another gene, PML, creating an abnormal PML-RARA protein. This fusion protein recruits repressor complexes to the same genes, freezing myeloid precursors in an immature, proliferating state instead of letting them mature. Pharmacological doses of retinoid agonists bind the RARA portion of the fusion protein, triggering its breakdown and lifting the block on gene expression. Released from repression, the leukemic cells resume their normal maturation program and differentiate into non-dividing, functional cells rather than being eliminated outright. This differentiation-inducing strategy is central to APL treatment and is mechanistically distinct from conventional chemotherapy that kills cells through DNA damage. It exemplifies a broader principle in oncology: some cancers arise from blocked cell maturation rather than purely from uncontrolled division, and reversing that block can itself be therapeutic.